Key Highlights:
- AI-Discovered Drug Shows Dupilumab-Level Efficacy: DeepCure’s DC-15442 delivers comparable results across multiple preclinical models of Type 2 inflammation.
- 100% In Vivo pSTAT6 Inhibition, No Off-Target Activity: A selective, non-degrader oral therapy built for long-term safety and broader patient access.
- MIT-Rooted AI Platform Accelerates Small Molecule Innovation: DeepCure leverages AI and physics to challenge the biologics-first standard in immunology.
Oral Option for Dupilumab-Class Patients
DeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics like dupilumab. Designed for chronic inflammatory conditions including asthma, eczema, and COPD, this AI-engineered STAT6 inhibitor mimics the efficacy of IL-4Ra-targeted antibodies, but in oral form. Its design avoids degradation of STAT6, aiming for both long-term safety and better patient adherence.
AI at the Helm of High-Precision Drug Design
DC-15442 is the product of DeepCure’s proprietary platform, which integrates AI with structural and chemical simulations to design targeted small molecules. The drug blocks STAT6 signaling by inhibiting protein interactions without disrupting baseline immune functions. With 100% inhibition of pSTAT6 in allergy models and no adverse off-target effects across 600+ screens, it highlights AI’s growing ability to replicate—and potentially surpass—biologic mechanisms.
Preclinical Performance Points to Transformative Potential
Across key disease models, DC-15442 equaled or outperformed dupilumab, reducing serum IgE and restoring lung function to near-normal. It also outpaced leading JAK inhibitors and corticosteroids, positioning it as a high-impact candidate for next-gen oral immunotherapies. Its clean safety profile—free from degradation-linked toxicity—reinforces its readiness for chronic-use scenarios.
MIT-Origin Biotech Scaling a New Drug Discovery Model
DeepCure, founded by MIT researchers, is rapidly building a pipeline of AI-generated drug candidates targeting traditionally hard-to-drug proteins. The nomination of DC-15442 as its second development asset marks another validation of its end-to-end discovery engine, aimed at reimagining how small molecules are developed for immune-mediated and chronic diseases.
By